ArticleCancer gene therapy2026
CagA promotes gastric cancer stemness and metastasis via DNMT1-mediated epigenetic silencing of BEX1.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) cytotoxin-associated gene A (CagA) critically contributes to gastric cancer (GC) pathogenesis, though its epigenetic control of cancer stemness is incompletely characterized. This study establishes that CagA enhances self-renewal capacity and metastatic potential in GC cells by elevating DNA methyltransferase 1 (DNMT1) expression. Upregulated DNMT1 catalyzes hypermethylation of the brain-expressed X-linked gene 1 (BEX1) promoter, resulting in transcriptional silencing of this tumor suppressor. Functional validation through tumorsphere/colony formation assays and transcriptomic profiling confirmed DNMT1-mediated BEX1 suppression as essential for sustaining stemness phenotypes. Crucially, in vivo models demonstrated that BEX1 overexpression reverses CagA-driven tumor growth and pulmonary metastasis, while BEX1 knockdown compromises the anti-tumor efficacy of DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (DAC). These findings define a novel pathogenic cascade wherein CagA initiates DNMT1-dependent epigenetic silencing of BEX1 to maintain cancer stemness. The mechanistic identification of this CagA-DNMT1-BEX1 axis provides a therapeutic rationale for targeting DNMT1 activity and restoring BEX1 function in metastatic GC. Schematic Illustration of the Molecular Mechanism by Which H. pylori CagA Protein Promotes the Maintenance of Stem Cell-Like Properties in GC Cells via DNMT1-Mediated BEX1 Methylation.
Indexed as
Identifiers
42463519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.